---
title: "Brii Biosciences Limited (02137.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/02137.HK.md"
symbol: "02137.HK"
name: "Brii Biosciences Limited"
industry: "Biotechnology"
---

# Brii Biosciences Limited (02137.HK)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | HK Market |
| Website | [www.briibio.com](https://www.briibio.com) |

## Company Profile

Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously admini...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-16T04:30:10.000Z

**Overall: D (0.65)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 45 / 53 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -24.06% |  |
| Net Profit YoY | -41.75% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.41 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1.13B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 31.20M |  |


**Multi Score**: D

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -14.06% | E |
| Profit Margin | -1305.67% | E |
| Gross Margin | 100.00% | A |

#### Growth Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -24.06% | E |
| Net Profit YoY | -41.75% | D |
| Total Assets YoY | -12.60% | E |
| Net Assets YoY | -11.79% | E |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -7.66% | D |
| OCF YoY | -24.06% | E |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.01 | E |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 2.07% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Brii Biosciences Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-14.06%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-1305.67%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "E",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-24.06%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-41.75%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-12.60%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-11.79%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-7.66%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-24.06%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.01",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "2.07%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | BEONE MEDICINES (HK.6160) | C | A | B | C | A | B |
| 02 | INNOVENT BIO (HK.1801) | B | A | C | B | A | B |
| 03 | 3SBIO (HK.1530) | A | B | C | A | C | B |
| 04 | BIOCYTOGEN-B (HK.2315) | A | A | C | D | B | B |
| 05 | HBM HOLDINGS-B (HK.2142) | A | A | C | B | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.71 | 17/70 | - | - | - |
| PB | 0.41 | 1/70 | 0.52 | 0.47 | 0.42 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-08-24T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 0 | 0% |
| Overweight | 0 | 0% |
| Hold | 1 | 100% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.55 |
| Highest Target | 2.00 |
| Lowest Target | 2.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/02137.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/02137.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/02137.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
